By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Humanigen (Formerly Known As KaloBios Pharmaceuticals, Inc.) 

1000 Marina Boulevard
Suite 250
Brisbane  California  94005-1878  U.S.A.
Phone: 650-243-3100 Fax: 650-243-3260


Humanigen, Inc. is a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative, accelerated business models. Lead compounds in the portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab. Lenzilumab has potential for treatment of various rare diseases, including hematologic cancers such as chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML)




CEO: Cameron Durrant

CSO: Morgan Lam

CFO: Dave Tousley

Key Statistics

Ownership: Public

Web Site: Humanigen
Symbol: HGEN


Company News
Humanigen (HGEN) Announces Completion Of Benznidazole Bioavailability Study 8/8/2017 12:40:43 PM
Bay Area's KaloBios (KBIO) Wants A Fresh Start, Changes Name To Humanigen 7/28/2017 7:08:42 AM
KaloBios (KBIO) Receives $5 Million In New Funding Commitment From Existing Investors 7/13/2017 10:40:11 AM
KaloBios (KBIO) Receives Orphan Drug Designation For Benznidazole In The Treatment Of Chagas Disease 7/12/2017 11:09:47 AM
KaloBios (KBIO) Release: Benznidazole IND For Chagas Disease Receives Clearance By FDA 6/27/2017 11:22:43 AM
KaloBios (KBIO) Upgrades Stock To OTCQB Market 6/26/2017 12:11:28 PM
KaloBios (KBIO) Submits IND Application For Benznidazole To FDA 5/30/2017 10:36:50 AM
KaloBios (KBIO) To Host Company Overview Webinar On May 10 5/3/2017 9:57:18 AM
KaloBios (KBIO) Release: Benznidazole On Track In Progress To IND And NDA Submissions 4/6/2017 11:21:54 AM
KaloBios (KBIO) Announces Positive Guidance From FDA For Benznidazole 1/6/2017 8:52:44 AM